Topotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy.
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
2001
|
| _version_ | 1826264749509181440 |
|---|---|
| author | Poynton, C Maughan, T Hasan, F Falk, S Shelley, M Smith, P |
| author_facet | Poynton, C Maughan, T Hasan, F Falk, S Shelley, M Smith, P |
| author_sort | Poynton, C |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T20:12:51Z |
| format | Journal article |
| id | oxford-uuid:2b2a8bc1-3c70-414c-95dc-053db8fa8210 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:12:51Z |
| publishDate | 2001 |
| record_format | dspace |
| spelling | oxford-uuid:2b2a8bc1-3c70-414c-95dc-053db8fa82102022-03-26T12:29:18ZTopotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2b2a8bc1-3c70-414c-95dc-053db8fa8210Symplectic Elements at Oxford2001Poynton, CMaughan, THasan, FFalk, SShelley, MSmith, P |
| spellingShingle | Poynton, C Maughan, T Hasan, F Falk, S Shelley, M Smith, P Topotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy. |
| title | Topotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy. |
| title_full | Topotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy. |
| title_fullStr | Topotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy. |
| title_full_unstemmed | Topotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy. |
| title_short | Topotecan in mantle cell lymphoma - A 21 day continuous infusion regimen may have advantages over intermittent therapy. |
| title_sort | topotecan in mantle cell lymphoma a 21 day continuous infusion regimen may have advantages over intermittent therapy |
| work_keys_str_mv | AT poyntonc topotecaninmantlecelllymphomaa21daycontinuousinfusionregimenmayhaveadvantagesoverintermittenttherapy AT maughant topotecaninmantlecelllymphomaa21daycontinuousinfusionregimenmayhaveadvantagesoverintermittenttherapy AT hasanf topotecaninmantlecelllymphomaa21daycontinuousinfusionregimenmayhaveadvantagesoverintermittenttherapy AT falks topotecaninmantlecelllymphomaa21daycontinuousinfusionregimenmayhaveadvantagesoverintermittenttherapy AT shelleym topotecaninmantlecelllymphomaa21daycontinuousinfusionregimenmayhaveadvantagesoverintermittenttherapy AT smithp topotecaninmantlecelllymphomaa21daycontinuousinfusionregimenmayhaveadvantagesoverintermittenttherapy |